Healthcare Industry News: RITA Medical
News Release - January 9, 2006
OmniSonics Announces Additions to Senior Management TeamWILMINGTON, Mass., Jan. 9 (HSMN NewsFeed) -- OmniSonics Medical Technologies, Inc., developer of the ResolutionŽ Endovascular System, today announced the appointment of Trent C. Reutiman, Vice President of Sales, and Jeffrey J. Vaitekunas, Ph.D., Chief Biophysicist, to its senior management team. The additions strengthen the Company's technical and sales leadership as it launches its first commercial product.
Mr. Reutiman joins the Company from RITA Medical Systems, Inc., where he was Vice President of Sales and Marketing. He brings to OmniSonics greater than 15 years of medical device sales experience. While at RITA, Mr. Reutiman assisted in transitioning the company through its IPO and provided key leadership as the sales team grew to greater than 45 reps. Mr. Reutiman's prior experience includes sales management positions with Cardio Thoracic Systems, a division of Guidant Corporation, and Cordis, a Johnson & Johnson company. Mr. Reutiman holds a B.S. in Business Administration from Colorado State University and a M.B.A. from the University of California, Irvine.
Dr. Vaitekunas is a nationally recognized scientist in the field of therapeutic ultrasound, holding 17 patents and authoring numerous publications. He played a key role in Johnson & Johnson's (J&J) successful acquisition and ongoing development of UltraCisionŽ and its Harmonic ScalpelŽ line of products. In addition, he is a Patent Agent licensed to practice law in front of the United States Patent and Trademark Office and will have significant responsibilities for OmniSonics' extensive patent estate. He holds a B.S.E.E. from Purdue University, a M.S. in Theoretical and Applied Mechanics from Northwestern University and a Ph.D. in Bioengineering and Engineering Mechanics from the University of Cincinnati.
"Trent and Jeff are critical components in the completion of the build-out of our senior management team," noted Richard G. Ganz, OmniSonics' President and Chief Executive Officer. "With our initial sales team in place, Trent will provide direction and leadership for the launch of our first product and keep the team focused on clinician satisfaction and revenue growth. His experience allows us to aggressively build out our rep organization. In the field of therapeutic ultrasound, Jeff is one of the most respected and knowledgeable scientists. He will lead the technical development of OmniWave(TM) technology for new applications throughout the vasculature. We are delighted to have them both as members of the team," he added.
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., headquartered in Wilmington, Massachusetts, is a privately held medical device company focused on bringing breakthrough products for vascular occlusive disease to market. The Company's patented OmniWave technology is the first technology that enables the delivery of acoustic energy over an entire active length of a small diameter wire. OmniWave is designed to have broad applications in peripheral and coronary vascular occlusive conditions.
About the Resolution Endovascular System
The Resolution Endovascular System consists of two primary components, the Generator and the Resolution System Kit. The Resolution System Kit consists of a handpiece with attached wire and accessory irrigation tubing. The Generator controls an electrical signal to power the handpiece. The handpiece converts the electronic signal from the generator to low-power ultrasonic energy transmitted down the length of the Resolution Therapeutic Wire. The Resolution Therapeutic Wire distributes ultrasonic energy waves that generate a cavitational streaming effect that breaks the fibrin bonds.
The Resolution Endovascular System is easy to set up; Power-on -- Plug-in -- Prime. Treatment with the Resolution Endovascular System utilizes typical interventional technique and is compatible with common interventional devices (5Fr and .035" wire compatibility).
For more information, please visit the Company's website at http://www.omnisonics.com.
Source: OmniSonics Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.